It took place yesterday. at the Italian Medicines Agency. the first Plenary Meeting of the Centers participating in "INTERCEPTOR", a study project that aims to identify the "marker" or "set of markers" capable of accurately predicting the conversion of the diagnosis of mild cognitive decline ( Mild Cognitive Impairment, MCI) in Alzheimer's disease, after 2 or 3 years of follow-up, in order to early identify those patients who will appropriately benefit from new therapies being tested.
The meeting was attended by representatives of the Coordinating Committee, of the four Expert Centers in charge of an expert reading of some biomarkers and of the 20 Centers for Cognitive Disorders and Dementia (CDCD) in which patients will be enrolled.
The Project, which has as its promoter the Institute of Neurology of the “A. Gemelli ”- Catholic University of the Sacred Heart of Rome, has a strategic nature and is financed by AIFA through the use of the funds flowing into the“ Extraordinary reserve for AIFA's institutional activities ”.